Insmed reported $-117321000 in Net Income for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Acelrx Pharmaceuticals ACRX:US $ -9.85M 0.9M
Alexion Pharmaceuticals ALXN:US $ 636M 100.2M
Arena Pharmaceuticals ARNA:US $ -146.1M 27.68M
Biomarin Pharmaceutical BMRN:US $ 12.94M 4.43M
Cytokinetics CYTK:US $ -61.55M 14.45M
Dynavax Technologies DVAX:US $ 4.47M 3.58M
Flexion Therapeutics FLXN:US $ -22208000 6.35M
Gilead Sciences GILD:US $ 1522M 207M
Heron Therapeutics HRTX:US $ -61.02M 8.4M
Insmed INSM:US $ -117321000 25.68M
Mirati Therapeutics MRTX:US $ -166.43M 30.75M
Novartis NVS:US $ 2896M 837M
Regeneron Pharmaceuticals REGN:US $ 3098.9M 1983.7M
Sarepta Therapeutics SRPT:US $ -81.4M 85.84M
Seattle Genetics SGEN:US $ -84.58M 36.84M
Ultragenyx Pharmaceutical RARE:US $ -122.43M 13.71M
Vertex Pharmaceuticals VRTX:US $ 66.92M 586.21M